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TITLE OF CASE  
Beware of bone pain with bisphosphonates 
SUMMARY  
 
A 71 year old lady who had been taking ibandronate for 10 years presented to an Endocrinology 
Department with persistent mid-thigh pain. Pelvic x-ray showed bilateral femoral cortical expan-
sion, indicating impending atypical femoral fractures. Atypical femoral fractures have been linked 
to long-term bisphosphonate therapy and have morbidity and mortality similar to that of hip frac-
tures. Such fractures can be averted by regular reviews of bisphosphonate therapy and vigilance 
for prodromal symptoms. This patient’s bisphosphonate therapy was stopped and fractures were 
avoided by treatment with vitamin-D and parathyroid hormone. 
BACKGROUND  
 
It has been estimated that osteoporosis affects 2.8 million people in the UK. Bisphosphonates can 
reduce the risk of hip fractures by 30–50% and vertebral fractures by 30–70%.[1] Paradoxically, 
bisphosphonate therapy has recently been associated with an increase in risk of one particular 
type of fracture, namely a transverse femoral diaphyseal fracture that tends to occur with minimal 
trauma, the so-called ‘atypical femoral fracture’ (AFF). These result in morbidity and mortality 
similar to that of hip fractures. AFFs are often preceded by a typical prodromal thigh pain so doc-
tors should therefore be vigilant for prodromal symptoms of atypical femoral fractures in patients 
on bisphosphonate therapy and adopt an appropriate therapeutic approach.[2] 
CASE PRESENTATION  
 
A 71 year old vegetarian lady of Indian origin presented to the Norfolk & Norwich University Hos-
pital Endocrinology Department in 2012 with generalised aches and pains. Her past medical his-
tory included osteoporosis diagnosed in 1999 on a DEXA scan, bilateral Colles’ fractures in 2008, 
and pernicious anaemia. Her regular medications were calcium carbonate 2,500 mg one tablet 
daily (Calcichew Forte), calcitriol (1,25-Dihydroxy-vitamin-D) 500ng daily, diclofenac 100mg daily, 
ibandronic acid 150mg monthly, started in 2002, and vitamin B12 injections. The ibandronic acid 
was started for osteoporosis and was chosen for the convenience of a once monthly oral prepara-
tion, the calcitriol had been prescribed for vitamin D deficiency. 
INVESTIGATIONS  
 
• DEXA 12/1/2011: T-scores -0.9 in the lumbar spine, -1.8 in the left hip, -1.6 left femoral neck 
(Z-scores of 1, -0.5 and 0 respectively) 
Blood tests 21/5/2012: 
• 25-OH-Vitamin-D 13 nmol/L (50 - 120) 
• Adjusted Calcium 2.33 mmol/L (2.10 - 2.60) 
• Alkaline Phosphatase 63 U/L (38 – 126) 
Blood tests 20/11/2012: 
• Parathyroid Hormone 3.7 pmol/L (1.6 - 6.9) 
• 25-OH-Vitamin-D 53 nmol/L (50 - 120) 
• Serum C-terminal telopeptide of type-1 collagen (CTX) 0.13 ug/L (0.10 - 0.50) 
• Serum Procollagen Type-1 Amino Terminal Peptide 14 ug/L (19 – 69) 
• Radiographs of hips and pelvis 10/12/2013: no bone or joint abnormality reported 
DIFFERENTIAL DIAGNOSIS  
Osteopenia with vitamin-D deficiency 
TREATMENT  
The patient was given 150000 IU of intramuscular vitamin-D (ergocalciferol) and continued iband-
ronic acid 150 mg monthly. Calcichew Forte was changed to Calcichew D3 Forte one daily. The 
generalised bone pain initially resolved but vitamin-D insufficiency recurred (25 OH D 36 mol/L) 
and right hip pain was present over the next year. 20,000IU cholecalciferol (vitamin-D) once 
weekly was administered commencing December 2013 for 8 months. 
OUTCOME AND FOLLOW-UP   
In August 2014, the patient now complained specifically of mid-thigh pain. Investigation results 
were as follows: 
 Serum C-terminal telopeptide of type 1 collagen 0.23 ug/L (0.10 - 0.50) 
 Serum Procollagen Type 1 Amino Terminal Peptide 24 ug/L (19 – 69) 
 25-OH-Vitamin-D 82 nmol/L (optimal 50 – 120) 
 Plain X-ray femurs: bilateral femoral cortical expansion (figure 1 and figure 2) 
Urgent bilateral femoral nailing was recommended following orthopaedic review but the patient did 
not want this treatment and after discussion the initial therapy was conservative management: 
 Ibandronic acid was stopped 
 Daily parathyroid hormone (Teriparatide 1-34 “Forsteo”) injections were commenced 20 
mcg od sc. 
 The patient was still receiving calcitriol at this stage as it had alleviated some of her mus-
culoskeletal pain and this was continued for the duration of her teriparatide therapy. 
 1000 IU vitamin D3 (cholecalciferol) daily for one year was also commenced. 
 After completion of Teriparatide therapy, the thigh pain was much improved bilaterally and 
follow up radiographs showed that the femoral cortical expansion was significantly im-
proved and the impending fractures had almost completely healed. 
DISCUSSION  
 The lifelong risk of having a fracture related to osteoporosis is approximately one in two for 
women and one in four for men.[2] Bisphosphonates have successfully been used to reduce this 
risk by increasing bone strength and stiffness, but reduce bone-remodelling and have been associ-
ated with atypical femoral fractures if used for more than 3 years.[2,3] The patient in this case 
study had been on ibandronate for 10 years. Her bone marker results reflected low bone remodel-
ling with CTX in keeping with decreased collagen resorption in response to ibandronate while her 
low serum procollagen type-1 amino-terminal peptide result reflected decreased type-1 collagen 
synthesis. The relative risk of atypical femoral fractures (AFFs) associated with bisphosphonate 
use has been estimated from 1.70 (95% CI, 1.22–2.37) to 55 (95% CI: 39–79) corresponding to 
an absolute risk of 11 (CI: 7–14) fractures per 10,000 person-years of use.[4, 5] These fractures 
are rare compared to typical osteoporotic fractures and so less of a public health concern but their 
impact on the individual warrants vigilance.[4] Mortality following atypical femoral fractures has 
been estimated to be 14% at 12 months and 25% at 24 months and morbidity is similar to that 
for hip fractures.[2,3].  
 
AFFs are thought to be insufficiency fractures arising from a fatigue mechanism associated with 
repetitive loading [6]. Possible risk factors for atypical femoral fractures during bisphosphonate 
therapy include use of multiple anti-resorptive medications, glucocorticoids or proton-pump inhibi-
tors, younger age when starting bisphosphonates, low pre-treatment bone turnover and normal 
bone mineral density.[3,7] The relative risk of atypical femoral fractures on alendronate compared 
to risedronate has been estimated as 1.9 (CI: 1.1–3.3).[5] Following cessation of bisphosphonate 
therapy the risk of atypical femoral fractures has been estimated to reduce by 70% per year.[5] 
Clinical features of atypical femoral fractures include prodromal pain for weeks to months, no sig-
nificant trauma, and bilateral fractures in some patients.[2,7] Radiographic features include peri-
osteal stress reaction, complete or incomplete, non-comminuted, transverse or short oblique sub-
trochanteric fractures, usually starting laterally and extending medially, proximal to the supracon-
dylar flare with (often bilateral) thickening of the lateral femoral cortices.[2,3] Intramedullary 
nails are recommended for repair of complete fractures and symptomatic incomplete fractures.  
 
Asymptomatic incomplete fractures can be managed conservatively with non-weight-bearing and 
re-evaluated after 2 to 3 months.[3] Imaging based on prodromal pain enabled cortical expansion 
to be identified in this patient before identifiable fractures occurred. Concentrations of bone-re-
modelling markers changed after bisphosphonate therapy was stopped and parathyroid hormone 
therapy was commenced (figure 3). Our report of a case with an impending AFF that healed with 
medical/conservative management is consistent with other reports in the literature [6] and adds 
support to the hypothesis that a partial AFF may be arrested and reversed before it has propa-
gated through the cortex. Teriparatide therapy has been associated with increasing the speed of 
the healing process but good clinical trial evidence of this is lacking. 
LEARNING POINTS/TAKE HOME MESSAGES 
 
 Bisphosphonate therapy should be re-evaluated 6-monthly after the first 5 years of use 
and stopping or pausing (drug holiday) should be considered for patients with low fracture 
risk and T-scores >-2.5 [8] 
 Patients on bisphosphonate therapy should be counselled to be vigilant for persistent thigh 
or groin pain.[2] 
 X-rays of the entire femur are essential for symptomatic patients.[7] If X-rays are normal, 
consider MRI or Radionuclide bone scintigraphy.[3] 
 If an atypical femoral fracture is confirmed, the contra-lateral femur should be evaluated 
radiologically.[3] 
 Femoral cortical expansion secondary to prolonged bisphosphonate therapy can sometimes 
be successfully managed medically without surgical intervention. 
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FIGURE/VIDEO CAPTIONS  
 
Figure 1: Pelvic radiograph demonstrating bilateral femoral cortical expansion at the proxi-
mal third of the femora (arrows).  
Figure 2: Left femoral radiograph showing periosteal stress reaction (arrow) 
Figure 3: Graphs of markers of calcium and bone metabolic indices (25 OH vitamin D; 1,25 
di OH vitamin D; serum C-terminal telopeptide cross links (CTX) and serum Procollagen Type 
1 Amino Terminal Peptide (P1NP) ) changes between 2012 and 2015. Ibandronic acid therapy 
was stopped in August 2014. 
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